Sobi Advances SEL-212 for Chronic Refractory Gout with FDA BLA Submission Initiation
Sobi Begins FDA Submission Process for SEL-212, Advancing Potential Treatment for Chronic Refractory Gout Sobi has commenced a rolling Biologics License Application (BLA) to the US Food and Drug Administration (FDA) for SEL-212, based on positive outcomes from the DISSOLVE I and II pivotal trials. SEL-212 represents an innovative biologic therapy aimed at addressing chronic … Read more